Introduction
A great number of regulatory proteins are modi®ed by conjugation with ubiquitin (Ub) or ubiquitin-like proteins (Ulp). This modi®cation acts as a targeting signal, delivering the modi®ed protein to dierent locations in the cell and modifying its activity, halflife, or interaction with other molecules (Ciechanover et al., 2000; Hochstrasser, 2000) . Ubiquitin modi®ca-tion of proteins plays an important role in many critical pathways including regulation of the cell cycle, modulation of the cellular response to stress and extracellular eectors, morphogenesis of neural networks, DNA repair, regulation of the immune and in¯ammatory responses, down-regulation of cell surface receptors and ion channels, and biogenesis of organelles (Ciechanover et al., 2000) . Deubiquitination, the reversal of this modi®cation, is carried out by deubiquitinating enzymes that are thiol proteases. The process of deubiquitination is now being recognized as a participant in the regulatory processes of the cell (Wilkinson, 1997; D'Andrea and Pellman, 1998) .
We have previously analysed gene expression patterns in non-small cell lung carcinoma (NSCLC) using the serial analysis of gene expression (SAGE) approach and identi®ed PGP9.5 as a protein highly expressed in primary lung cancers and lung cancer cell lines (Hibi et al., 1998) . PGP9.5 represents one of the members of the ubiquitin carboxy terminal hydrolase (UCH) family, UCH-L1. Three human UCH isozymes have been cloned which exhibit marked tissue speci®city (Wilkinson, 1997) . UCH-L1 was found to be only localized to the brain and testis (Chung and Baek, 1999) and also thought to play a role in the development of some forms of Parkinson's disease (Wilkinson, 2000) . We have observed aberrant PGP9.5 expression in 22 of 24 lung cancer cell lines and in 54% of 98 primary NSCLC cases. Moreover, PGP9.5 expression was strongly associated with advanced stage lung cancers (Hibi et al., 1999) .
Biochemically, UCH isoforms tend to hydrolyze monoubiquitinated substrates (Larsen et al., 1998) . These monoubiquitinated substrates are not targeted for degradation by the 26S proteasome pathway, but this reversible modi®cation is being recognized as an important regulatory strategy (Wilkinson, 1997 (Wilkinson, , 2000 . Recently, UCH-L3 was shown to function as a terminal hydrolase for Nedd 8, an ubiquitin-like protein as well as ubiquitin (Wada et al., 1998) . Because little is known regarding UCH-L1 speci®c substrates or its biological activity in vivo, and our previous results indicated that PGP9.5 may play a role in lung cancer tumorigenesis, we used a yeast twohybrid system to identify proteins that interact with PGP9.5 in an eort to obtain further insights into the biological function of this protein.
The results presented here demonstrate the unbiased interaction of PGP9.5 with JAB1, a protein initially described as a co-activator of c-jun (Claret et al., 1996) . JAB1 was later shown to be a component of a novel protein complex called signalosome (Seeger et al., 1998) . Several studies have also shown that JAB1 promotes the phosphorylation and cytoplasmic translocation of p27
Kip1 for its subsequent degradation in the cytoplasm (Tomoda et al., 1999) . Our results show that PGP9.5 associates in vivo and in vitro with JAB1. The two proteins are localized throughout the cells. However, they appeared to be able to form a heteromeric complex that includes p27
Kip1 and can co-localize to the nucleus of lung cancer cells. Furthermore, the nuclear localization of PGP9.5 and JAB1 coincided with a reduced nuclear staining of p27
Kip1 during serum restimulation. In contrast, when cells were contact inhibited, both PGP9.5 and JAB1 were redistributed in the cytoplasm while p27
Kip1 was present only in the nucleus. These observations suggested that PGP9.5 might play a role in lung cancer growth by regulating the level of nuclear JAB1, which can then lead to an increased degradation of p27 Kip1 .
Results

Identification of proteins interacting with PGP9.5
A yeast two-hybrid screen was used to identify candidate proteins that interact with PGP9.5 in an expression cDNA library derived from fetal brain fused with the Gal4 transactivation domain. The library was screened three times and a total of 1.67610 7 independent clones were analysed (Table 1) . Several speci®cally interacting cDNA clones were identi®ed that were positive for the expression of the selection markers (histidine and adenine). Four cDNA clones interacted speci®cally with PGP9.5 upon reconstitution analysis. Subsequent sequence analysis showed that two of the clones had an identical 1.4-kb insert with 100% homology to the human ubiquitin-conjugating enzyme UBC9 (Shen et al., 1996) . Another clone with a 2.5 kb insert was identical to RanBPM, a Ran associated protein that is present throughout the cells (Nishitani et al., 2001 ). The fourth clone had a 1.05 kb insert identical to a human Jun activation domainbinding protein that was initially called p38 JAB1 (Claret et al., 1996) . We selected p38 JAB1 (JAB1) for further analysis because of its involvement in c-jun activation and p27
Kip1 degradation.
Coprecipitation of PGP9.5 and JAB1 from cell lysates
In order to determine whether PGP9.5 and JAB1 associate in vivo, we prepared total lysates from H1299 cells that express both PGP9.5 and JAB1 proteins. Because anti-PGP9.5 polyclonal and monoclonal antibodies could not recognize the native form of PGP9.5, complexes between endogenous PGP9.5 and JAB1 proteins were precipitated using anti-JAB1 antibody attached to a protein A/G-beads column. The presence of PGP9.5 in the complex was detected by subsequent Western blot using both antibodies. As shown in Figure 1a , PGP9.5 and JAB1 proteins coprecipitated when the JAB1 antibody was used. In contrast, coprecipitation reactions with either an irrelevant antibody (rabbit polyclonal antibody against hemagglutinin, anti-HA) or the protein A/G-beads alone failed to precipitate PGP9.5, indicating that the PGP9.5/JAB1 interaction was speci®c.
Colocalization of PGP9.5 and JAB1 in vivo
We next examined whether the association between PGP9.5 and JAB1 resulted in colocalization of the two proteins in vivo using double immuno¯uorescence staining of the H1299 cells. As shown in Figure 1b , PGP9.5 and JAB1 were present throughout the cytosol in exponentially growing H1299 cells and JAB1 was also distributed as clusters in the perinuclear space as shown previously (Li et al., 2000) . Moreover, both PGP9.5 and JAB1 colocalized to the nuclei, where they accumulated as relatively large aggregates. Similar patterns of protein localization were observed in other tested lung cancer cell lines (data not shown). To determine the nuclear distribution of PGP9.5 and JAB1, an antibody to ®brillarin, a protein that is only present in the nucleolus in interphase cells (Nicol et al., 2000) was used together with the JAB1 antibody. The result indicated that PGP9.5 and JAB1 colocalized predominantly to the nucleoli in the nucleus (Figure 2 , top panel). 
Nucleolar localization and interaction of p27
Kip1 with JAB1 and PGP9.5
Since JAB1 was known to be involved in the translocation of p27 Kip1 to the cytoplasm, we tested whether these three proteins colocalized to the same subnuclear compartment using double immunostaining with p27
Kip1 antibody and either PGP9.5 or JAB1 antibody. As shown in Figure 1b , PGP9.5 and JAB1 were detected both in the cytoplasm and in the nucleoli, whereas p27
Kip1 was detected primarily in the nucleus with strong staining to the nucleoli ( Figure  2 ). Interestingly, the nuclear localization for p27 Kip1 was very similar to the colocalization of both PGP9.5 and JAB1. We, therefore, reasoned that these three proteins might be able to form a complex in the nucleoli. H1299 cell lysate used for immunoprecipitation with the JAB1 antibodies and previously immunoblotted with the PGP9.5 antibody (Figure 1a ) was separately examined by Western analysis using the anti-p27
Kip1 antibody. As shown in Figure 3a , p27
Kip1
protein was also present in the JAB1 complex where PGP9.5 was observed. This in vivo interaction between JAB1 and p27 Kip1 data is consistent with the previous report using in vitro synthesized proteins (Tomoda et al., 1999) . Furthermore, the interaction between PGP9.5 and p27
Kip1 appeared to be restricted to the nuclear form of the p27
Kip1 since only K25020 antibody that recognizes mainly the nuclear form of p27 Kip1 ( Figure 3b ) was able to coprecipitate with PGP9.5 from the H1299 cell lysate containing both proteins ( Figure  3c ). In contrast, PGP9.5 could not be precipitated by this same antibody using the H1155 cell lysate that was devoid of the p27
Kip1 protein (Figure 3d ).
Cellular redistribution of PGP9.5, JAB1 and p27
Kip1 during serum restimulation
It has been shown that p27 Kip1 nuclear localization is a prerequisite for it to function as a cell cycle regulator (Polyak et al., 1994) . JAB1 interacts speci®cally with p27
Kip1 and causes its translocation from the nucleus to the cytoplasm, decreasing the amount of p27 Kip1 in the cell by accelerating its degradation via proteosomes. Our in vivo protein localization data suggested that, instead of regulating JAB1 via deubiquitination, PGP9.5 may contribute to the down regulation of p27
Kip1 by interacting and redistributing JAB1 between the cytoplasm and the nucleus. To test this, we subjected H1299 cells to growth without the serum for 24 h and then examined the cellular distribution of these proteins during serum re-stimulation. As shown in Figure 4 , the cellular level of PGP9.5 and JAB1 remained constant while p27 Kip1 was at its lowest level 4 h after reintroduction of serum into the media. This change of p27
Kip1 level is also similarly observed by immuno¯uorescence analysis shown in Figure 5 . At four hours after serum re-stimulation, H1299 cell nucleus was mostly devoid of p27 Kip1 while PGP9.5 and JAB1 were distributed both in the cytoplasm and JAB1 and anti-PGP9.5 antibodies and visualized using rhodamine and uorescein labeled secondary antibodies, respectively. The images were overlapped (Merge) to reveal colocalization the nucleus ( Figure 5, top panel) . In contrast, hours after serum re-stimulation, when these same cells were allowed to grow to con¯uency and become contact inhibited, p27
Kip1 gradually accumulated in the nucleus while PGP9.5 and JAB1 were redistributed to the perinuclear compartment and the cytoplasm of the cells ( Figure 5, lower panel) .
Discussion
Using the yeast two-hybrid screening, we identi®ed JAB1 as one of the cellular partners for PGP9.5. The JAB1 is a multi-function protein that was ®rst identi®ed by a yeast two-hybrid screen through its ability to associate with the N-terminal c-Jun activation domain. Subsequently, this interaction was shown to potentiate c-jun transactivation and JAB1 was reported to be a nuclear protein (Claret et al., 1996) . Later, JAB1 was identi®ed as part of a large multiprotein complex named the signalosome (Seeger et al., 1998) . This complex, localized to the cytosol, also contained the mammalian homologues of the plant COP9 complex involved in light-mediated signal transduction (Wei et al., 1998) . Interestingly, it was shown that JAB1 possesses kinase activity which phosphorylates the N-terminal activation domain of c-jun, an essential step for c-jun mediated transactivation, as well as IkBa, a regulatory subunit of the NFkB transcription factor (Seeger et al., 1998) . It was also reported that the macrophage migration inhibition factor (MIF) binds to JAB1 and negatively regulates JAB1-controlled pathways (Kleemann et al., 2000) .
JAB1 was also shown to interact with p27 Kip1 in the nucleus, translocate it to the cytoplasm and facilitate its degradation in a 26S proteasome-dependent manner (Tomoda et al., 1999) . p27
Kip1 plays a pivotal role in the negative control of cell growth (Polyak et al., 1994; Hengst et al., 1994) . The activity and the cellular level of p27
Kip1 is mediated through several mechanisms including the inhibition of its binding to CDKs, nuclear sequestration, and degradation via the ubiquitin mediated proteosomes (Slingerland and Pagano, 2000) . Clinically, the reduced level of p27
Kip1 protein is frequently observed in human cancers, including breast, lung (Hommura et al., 2000) , prostate, colon (Yao et al., 2000; Hirano and Minamoto, 2000) skin, and ovarian cancers. Decreased expression of p27
Kip1 was shown to correlate with cancer development and poor survival (Slingerland and Pagano, 2000). The exact mechanism that Kip1 colocalization in the nucleolus. Upper panel, H1299 cells were assayed for endogenous JAB1 and ®brillarin localization by immuno¯uorescence using anti-p38 JAB1 and anti-®brillarin antibodies and rhodamine (red) and uorescein (green) labeled secondary antibodies, respectively. Middle and lower panels, cellular distribution and co-localization of JAB1, PGP9.5 with p27
Kip1 in the nucleolus, respectively. H1299 cells were assayed for endogenous PGP9.5, JAB1 and p27 Kip1 localization by immuno¯uorescence using respective antibodies as indicated. Co-localization with p27 Kip1 was primarily observed in the nucleolus. Nuclei were counterstained with DAPI (blue). The images were overlapped (Merge) to determine co-localization underlies this decreased p27
Kip1 expression is not known but overexpression of the HER-2/neu oncogene was shown to cause translocation of p27
Kip1 and JAB1 to the cytoplasm, thereby facilitating p27
Kip1 degradation (Yang et al., 2000) .
The relative distribution of JAB1 between the nucleus and the cytoplasm probably re¯ects the dierent roles of this protein as a transcriptional coactivator, as part of a cytoplasmic multiprotein complex with kinase activity, and as a factor in p27 Kip1 translocation. Importantly, the physiological and/or pathological functions of cellular proteins are often re¯ected by their subcellular localization patterns, particularly in speci®c subnuclear organelles (Mattsson et al., 2001) . Although JAB1 is not a known substrate of ubiquitination, its colocalization and interaction with PGP9.5 suggests that it may be regulated by PGP9.5 through nuclear transportation. Consistent with this notion is the fact that the functions of the two other interacting proteins, UBC9 and RanBPM, in the yeast two-hybrid assay also suggest that PGP9.5 may indeed participate in protein tracking between cellular compartments. UBC9 is a ligase for an ubiquitin like protein, SUMO (Sampson et al., 2001) . SUMO modi®cation is thought to be involved in the nuclear transport of the modi®ed proteins (Lee et al., 1998; Melchior, 2000) . RanBPM is a newly identi®ed factor that interacts with Ran (Nishitani et al., 2001 ), a small GTP binding protein involved in nuclear trac of many proteins (Izaurralde et al., 1997) . Thus, although the exact nature of cellular redistribution of JAB1 and PGP9.5 between the nucleus and cytoplasm remains to be determined, the intimate involvement of PGP9.5 with JAB1 and p27
Kip1 proteins in the nucleus (Figure 1a ) was also blotted separately using the anti-p27
Kip1 antibody. Endogenous JAB1-p27
Kip1 complexes were immunoprecipitated from H1299 cell lysate with anti-JAB1 antibody and detected antip27
Kip1 antibody. Precipitation with anti-HA antibody served as a negative control. (b) Dierent anti-p27 Kip1 antibodies recognize dierent forms of p27 Kip1 . Two slides prepared from H1299 collected from the same¯ask were probed separately with two dierent anti-p27
Kip1 antibodies. K25020 recognizes mainly the nuclear form of p27 Kip1 whereas M197 recognizes mostly the cytoplasmic form of this protein. (c) PGP9.5 is in the same complex with p27
Kip1 in H1299 cell lysate as detected by immunoprecipitation using K25020 anti-p27 Kip1 (K25020), but not M197 antibody. (d) PGP9.5 would not be precipitated from H1155 cell lysate (devoid of 27 Kip1 ) using anti-p27
Kip1 antibody (K25020). IP: immunoprecipitation. C: Precipitation with beads alone. WCE: whole cell extract. WB: Western blot antibody Figure 4 p27 Kip1 , PGP9.5 and JAB1 levels after serum starvation and re-stimulation. H1299 cells were grown for 24 h in the absence of serum (7) then re-stimulated with serum at 4, 8, 24 and 32 h as indicated before harvest. Levels of p27 Kip1 , PGP9.5 and JAB1 were compared to H1299 cells grown to 40 and 100% con¯uence in the presence of serum. Actin was used to normalize the amount of protein loaded in the gel suggests that PGP9.5 may play a role in JAB1 mediated-degradation of p27 Kip1 . To this end, the high levels of PGP9.5 protein often observed in lung cancers may explain, in part, the observation of low p27 Kip1 protein levels in lung cancers.
Materials and methods
Yeast two-hybrid screening
The full length PGP9.5 cDNA (782 bp) was subcloned into the pBD-Gal4Cam vector (Stratagene) containing the yeast TRP1 marker between the SalI and PstI sites to generate a fusion protein downstream of the Gal4 DNA binding domain (BD). This plasmid was then used as a bait to screen a human fetal brain Matchmaker cDNA library (Clontech), containing the Leu2 gene marker (Clontech) and fusion products downstream of the Gal4 activation domain (Gal-AD). The yeast strain PJ69-4A (James et al., 1996) was transformed by the lithium acetate method, as described (Gietz et al., 1995) , with the bait plasmid, then with the Matchmaker cDNA library. The transformants were plated on medium lacking leucine, tryptophan and histidine (7L, 7T, 7H) for up to 3 weeks at 308C. Colonies were picked and replated on 7L, 7T, 7H agar plates. Those that grew in the second plate were plated in medium lacking leucine, tryptophan and adenine (7L, 7T, 7A). The positive colonies were then subjected to several rounds of culture in SC without tryptophan (7T) to eliminate the bait plasmid. Each Trp + clone was tested again for activation of the reporter genes to eliminate those that transactivate the reporter gene in the absence of the bait plasmid. Finally, the plasmid DNA was isolated from the positive yeast clones, ampli®ed in E. coli, and analysed by automated DNA sequencing. These plasmids were also used to reconstruct the in vivo interaction by transforming them back into the original yeast strain containing the bait plasmid.
Cell culture
The lung cancer cell lines H1299, H157 and A549 were maintained in RPMI medium containing 10% fetal bovine serum (FBS), whereas H1155 was maintained in RPMI with 5% FBS. The subcellular localization of the proteins was determined by immuno¯uorescence staining. , PGP9.5 and JAB1 localization in H1299 cells during serum re-stimulation. Cells were grown for 24 h in the absence of serum and then examined at 4, 12, 24 and 32 h after serum re-stimulation. H1299 cells were assayed for endogenous PGP9.5, JAB1 and p27
Kip1 distribution by immuno¯uorescence using anti-JAB1, anti-PGP9.5, and anti-p27 Kip1 antibodies and rhodamine and¯uorescein labeled secondary antibodies. Nuclei were counterstained with DAPI
Western blot analysis
Cell extracts were prepared in LSLD buer (50 mM HEPES, pH 7.4, 50 mM NaCl, 10% glycerol, 0.1% Tween 20, 1 mM DTT, 0.3 mM sodium orthovanadate, 50 mM NaF, 80 mM bglycerophosphate, 1 mM PMSF and protease inhibitor Complete TM tablet) and subjected to ®ve cycles of sonication (Polyak et al., 1994) . Fifty microliters of the protein was mixed with an equal volume of 26 loading buer (125 mM Tris-HCl pH 6.8, 4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% b-mercaptoethanol), incubated at 958C for 3 min, and loaded in 4 ± 20% SDS Tris HCl gels (Novex). After electrophoresis, proteins were transferred to nitrocellulose membranes at 280 mA for 1 h. The membrane was blocked by incubation in PBST 5% nonfat dry milk for 1 h, then incubated with the primary antibody overnight at 48C. After washing in PBST, the membranes were incubated either with peroxidase-conjugated anti-rabbit or anti-mouse IgG (Amersham-Pharmacia-Biotech) for 1 h at room temperature. Antibody binding was detected using the ECL system (Amersham). The antibodies used were polyclonal anti-JAB1 (N-17) from Santa Cruz Biotechnology, monoclonal anti-p27
Kip1 (K25020, clone 57) from Transduction Laboratories (Lexington, KY, USA), polyclonal anti-p27
Kip1 (M197) from Santa Cruz Biotechnology, polyclonal and monoclonal anti-PGP9.5 from Biogenesis (New Fields, UK) and monoclonal anti-®brillarin (AFB01) from Cytoskeleton (Denver, CO, USA).
Co-immunoprecipitations
Polyclonal anti-JAB1 antibody was cross-linked to protein A/ G beads using the Immunopure IgG plus orientation kit (Pierce) according to the manufacturer instructions. Four milligrams of H1299 protein extract, prepared with LSLD buer, was applied to the column and, after 1 h incubation at 48C, the column was washed with binding buer. The bound protein was eluted and the fractions with higher protein content were collected and loaded in a 4 ± 20% SDS Tris-HCl gel. Columns without bound antibody or with an irrelevant polyclonal antibody (rabbit anti-HA, Pierce) were used under the same conditions to serve as negative controls. For p27 Kip1 immunoprecipitation, H1299 or H1155 cell lysates (4 mg total protein), prepared in LSLD buer, were incubated with the antibody for 2 h at 48C with gentle agitation. Immunocomplexes bound to protein A/G beads were collected by centrifugation and washed several times in LSLD buer. Immunoprecipitated proteins were resolved in 4 ± 20% SDS ± PAGE gels followed by Western blot.
Immunofluorescence staining
Cells were harvested by trypsinization, washed with PBS, and cytospun onto the microscope slides. Cells were ®xed with 3% paraformaldehyde in PBS (138 mM NaCl, 2.7 mM KCl, pH 7.4) for 10 min at room temperature, permeabilized with 0.2% Triton X-100 in PBS for 2 min and blocked with 5% goat serum in PBST (PBS 0.1% Tween 20) for 30 min at room temperature. Cells were then incubated with the primary antibody overnight at 48C and, after three washes in PBST, were incubated with a mixture of secondary antibodies (FITC-conjugated goat anti-mouse IgG and Rhodamine-conjugated goat anti-rabbit IgG, Santa Cruz Biotechnology). After washing, the slides were incubated with 0.02 mg/ml DAPI (Sigma) to visualize the nuclei. The slides were mounted in Vectashield and analysed under a Zeiss Auxiphot epi¯uorescence microscope.
